Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity |
| |
Authors: | Verlinden Lieve Verstuyf Annemieke Verboven Christel Eelen Guy De Ranter Camiel Gao Ling-Jie Chen Yong-Jun Murad Ibrahim Choi Mihwa Yamamoto Keiko Yamada Sachiko Van Haver Dirk Vandewalle Maurits De Clercq Pierre J Bouillon Roger |
| |
Institution: | Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Herestraat 49, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium. |
| |
Abstract: | Deletion of C19 in the structure of 1 alpha,25-dihydroxyvitamin D3 1,25(OH)2D3] does not substantially alter the biological potency but prevents the conversion between the vitamin and the previtamin form. Hence, this modification allows the study of locked previtamin and vitamin forms. The locked 19-nor-1,25(OH)2-previtamin D3 analog (19-nor-previtamin D) had a low biological activity and was a rather weak activator of the genomic signal transduction pathway. 19-Nor-trans-decalin-1,25(OH)2-vitamin D3 (19-nor-TD-vitamin D), characterized by the presence of a trans-fused decalin CD-ring system, was 10-fold more potent than the parent compound and was a potent activator of the genomic signal transduction pathway. Surprisingly, the previtamin, 19-nor-trans-decalin-1,25(OH)2-previtamin D3 (19-nor-TD-previtamin D), was as potent as 1,25(OH)2D3 in inhibiting cell proliferation and inducing cell differentiation and represents the first previtamin structure with pronounced vitamin D-like activity. Furthermore, this compound interacted as efficiently as 1,25(OH)2D3 with the vitamin D receptor (VDR), retinoid X receptor (RXR), coactivators, and DNA, which illustrated its potent ability to activate the genomic signal transduction pathway. Analysis of the transactivation potency of 12 VDR point mutants after stimulation with 19-nor-TD-previtamin D revealed that this analog used the same contact points within the receptor as did 1,25(OH)2D3. This could be confirmed by modeling analysis of this compound in the ligand binding pocket of VDR. In conclusion, a previtamin D3 analog is presented with genomic activities equivalent to 1,25(OH)2D3. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|